Virax Biolabs (VRAX) Enterprise Value (2021 - 2023)

Virax Biolabs (VRAX) has 3 years of Enterprise Value data on record, last reported at -$9.4 million in Q1 2023.

  • For Q1 2023, Enterprise Value fell 42888.32% year-over-year to -$9.4 million; the TTM value through Mar 2023 reached -$9.4 million, down 42888.32%, while the annual FY2023 figure was -$9.4 million, 42888.32% down from the prior year.
  • Enterprise Value reached -$9.4 million in Q1 2023 per VRAX's latest filing, down from -$21756.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$17621.0 in Q1 2021 and bottomed at -$9.4 million in Q1 2023.
  • Average Enterprise Value over 3 years is -$3.1 million, with a median of -$21756.0 recorded in 2022.
  • Peak YoY movement for Enterprise Value: dropped 23.47% in 2022, then crashed 42888.32% in 2023.
  • A 3-year view of Enterprise Value shows it stood at -$17621.0 in 2021, then fell by 23.47% to -$21756.0 in 2022, then plummeted by 42888.32% to -$9.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$9.4 million in Q1 2023, -$21756.0 in Q1 2022, and -$17621.0 in Q1 2021.